Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease by Mackinnon, Alexander C et al.
Paxillin expression and ampliﬁcation in early lung
lesions of high-risk patients, lung adenocarcinoma
and metastatic disease
Alexander C Mackinnon,
1 Maria Tretiakova,
1 Les Henderson,
2 Rajendra G Mehta,
3
Benjamin C Yan,
1 Loren Joseph,
1 Thomas Krausz,
1 Aliya N Husain,
1 Mary E Reid,
4
Ravi Salgia
2
ABSTRACT
Background Paxillin is a modular protein that localises to
cell adhesion sites where it facilitates bidirectional
communication between the intracellular actin
cytoskeleton and the extracellular matrix. These complex
and dynamic interactions are essential for cell adhesion,
cell migration and cell survival. The authors have
previously demonstrated that paxillin is overexpressed in
lung cancer tissues and identiﬁed somatic paxillin
mutations in 9% of lung cancers. A murine in vivo
xenograft model of the most common paxillin mutation
(A127T) showed increased cell proliferation and invasive
tumour growth, establishing an important role for paxillin
in the development of lung cancer.
Methods The authors analysed 279 bronchoscopy-aided
biopsy specimens from 92 high-risk patients.
Adenocarcinoma with bronchioloalveolar features and
pure bronchioloalveolar carcinoma (BAC) were analysed
with ﬂuorescence in situ hybridisation (FISH) and
immunohistochemistry (IHC).
Results Paxillin is overexpressed in premalignant areas
of hyperplasia, squamous metaplasia and goblet cell
metaplasia, as well as dysplastic lesions and carcinoma
in high-risk patients. Concordance between increased
paxillin gene copy number and paxillin overexpression
was observed in cases of adenocarcinoma eusomic for
chromosome 12.
Conclusions Paxillin overexpression occurs during the
earliest stages of lung cancer development. FISH and IHC
analysis of lung adenocarcinoma suggests that relatively
small-scale genomic rearrangements of chromosome
12 are associated with paxillin overexpression in lung
adenocarcinoma.
INTRODUCTION
Lung cancer is the leading cause of cancer death in
the USA. Most often, lung cancer is diagnosed
when the disease is advanced, resulting in limited
therapeutic options and corresponding poor
survival times. At the same time, advances in early
detection through the use of low-dose spiral CT
imaging clearly enhance the ability to detect lung
cancer at early stages when therapeutic interven-
tion can potentially extend life.
1 2 Autoﬂuorescence
bronchoscopy (AFB) is a potential method for
identifying high-grade dysplasia and carcinoma in
situ within the central airway.
3e6 However, AFB
has low positive predictive value and low speci-
ﬁcity, since biopsy interpretation is confounded by
the fact that not all premalignant and preinvasive
lesions progress to lung cancer,
7 and low-grade
dysplasia, inﬂammation, hyperplasia, metaplasia
and granulation tissue all have abnormal AFB
patterns.
8 Hence, despite improvements in early
lung cancer detection, it is not yet evident that
early detection by CT or AFB results in mortality
reduction. Therefore, discovering clinically impor-
tant lung cancer biomarkers to identify patients at
high risk of developing lung cancer is critical to
improving lung cancer diagnosis and treatment.
We recently identiﬁed somatic mutations in the
gene paxillin
9 in lung cancer. The paxillin gene
codes for a 68 kDa focal adhesion molecule which is
recruited to nascent cell adhesion sites upon acti-
vation of ab integrin heterodimers.
10 Paxillin serves
as a scaffold for additional structural proteins and
regulatory proteins that collectively promote
changes in actin dynamics leading to regulation of
cell adhesion, migration and survival. These
proteineprotein interactions are regulated by
phosphorylation of paxillin via a large number of
kinases providing a mechanism for dynamic control
of the assembly and disassembly of large macro-
molecular complexes.
11 Tyrosine phosphorylation
of paxillin indirectly activates members of the Rho
family of G-proteins leading to the formation of
ﬁlopodia, lamellipodia and stress ﬁbres, which are
all actin-based cellular structures localised at the
leading edge of migrating cells.
12 Paxillin promotes
cell survival via its interaction with Bcl-2
91 31 4
during development, and paxillin and Bcl-2 coloc-
alise in lung cancer tissue.
9 Paxillin is often over-
expressed in lung cancer, suggesting that it may
contribute to malignancy and serve as a useful
biomarker for diagnosis of lung cancer and a cellular
target for lung cancer treatment.
In order to further characterise the role of paxillin
during lung cancer development and assess its
utility as a biomarker, we examined paxillin
expression and localisation in bronchial biopsy
specimens from patients at high risk of developing
lung cancer. We observed early and persistent
overexpression of paxillin during lung cancer
development in high-risk patients. As paxillin
overexpression is observed in both early neoplastic
lesions and lung cancer, we used ﬂuorescence in situ
hybridisation (FISH) to demonstrate that paxillin
gene copy number is often ampliﬁed in lung
adenocarcinoma and pure bronchioloalveolar carci-
noma (BAC). We also show that increased paxillin
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with chromosome 12 eusomy.
METHODS
Patient and sample selection
The high-risk patients and corresponding biopsy samples
examined in this study have been previously described.
15
Patients’ clinical and pathological information was obtained
from a lung bronchoscopy database (Roswell Park Cancer
Institute) and a lung cancer patient database (University of
Chicago) according to each institutional review board protocol.
The patients seen at Roswell Park did not have cancer at the
time they were evaluated with bronchoscopy. They had at least
two risk factors for cancer: previous history of lung cancer with
no evidence of disease for >2 years before the current biopsy;
diagnosis of chronic obstructive pulmonary disease; asbestos-
related lung disease
16; >20 pack-year cigarette smoking history.
These comprehensive databases include clinical information and
risk factor data such as age, gender, smoking status, medical
history, occupational exposure, pathological diagnosis, tumour
stage (TNM (tumour/nodes/metastasis)) and tumour grade.
Histological examination
H&E-stained slides of bronchial biopsy samples from 105
patients were reviewed by two pathologist (ACM and MT) and
categorised according to World Health Organization (WHO)
classiﬁcations.
17 Of these, 92 contained sufﬁcient respiratory
mucosa to be evaluated. ‘Premalignant’ changes include hyper-
plasia, squamous metaplasia and goblet cell metaplasia. ‘Prein-
vasive’ epithelial lesions include atypical adenomatous
hyperplasia (AAH), dysplasia and carcinoma in situ.
Immunohistochemistry
Tissue microarray (TMA) parafﬁn sections were deparafﬁnised
in xylene, rehydrated through graded ethanol solutions to
distilled water, and then washed in Tris-buffered saline.
Antigen retrieval was carried out by heating sections in ETDA
buffer (pH¼9) for 15 min in a microwave oven. Endogenous
peroxidase activity was quenched by incubation in 3% H2O2 in
methanol for 5 min. Non-speciﬁc binding sites were blocked
using Protein Block (Dako, Carpinteria, California, USA) for
20 min. Tissue sections were incubated for 1 h at room
temperature with the mouse monoclonal paxillin antibody
(clone 5H11, dilution 1:200; Neomarkers, Freemont, California,
USA) followed by 30 min incubation with goat anti-mouse IgG
conjugated to a horseradish peroxidase-labelled polymer
(Envision+ System; DakoCytomation, Carpinteria, California,
USA). Slides were developed for 5 min with 3,39-diamino-
benzidine chromogen and counterstained with haematoxylin.
Negative controls were performed by replacing the primary
antibody step with non-immune mouse immunoglobulins.
Immunostaining intensity in the cytoplasm was scored as
follows: 0¼no staining; 1¼weak staining; 2¼moderate
staining; and 3¼strong staining. In this study, immunohisto-
chemistry (IHC) scores of 2 and 3 were both interpreted as
overexpression. For comparison between means of two groups,
S t u d e n ttt e s to rc
2 test was used.
KRAS and EGFR mutation analysis
Sections 4 mm thick were cut from formalin-ﬁxed, parafﬁn-
embedded tissue samples and placed on to membrane-coated
laser capture microscopy slides (LCM; Leica, Wetzlar, Germany.).
Slides were deparafﬁnised in xylene, rehydrated through
gradient ethanol, stained with H&E, and dehydrated in ethanol.
Target lesions were identiﬁed and isolated by LCM. Tissue
fragments were digested overnight in proteinase K (10 mg/ml),
DNA was puriﬁed using Qiagen MinElute kits, and resuspended
in 10 mM Tris/HCl, pH 8.0.
Point mutations in KRAS codons 12 and 13 were identiﬁed
using a Light Cycler 2.0 as described by Nikiforova et al.
18 In brief,
puriﬁed DNAwas used to generate a PCR amplicon using primers
(K-rasF1: 59-AAGGCCTGCTGAAAATGACTG; K-rasR1:
59-GGTCCTGCACCAGTAATATGCA) that ﬂank the KRAS
codon 12/13 mutational hotspot. Using a pair of ﬂuorescently
labelled anchor and sensor oligonucleotides (KRASanc1: 59-
CGTCCACAAAATGATTCTGAATTAGCTGTATCGTCAAGGCA
GT-ﬂuorescein; KRASsnsr1: 59-LC Red640-TGCCTACGCCAC-
CAGCTCCAA-phosphate), ampliﬁcation and mutation detection
was accomplished via ﬂuorescence resonance energy transfer. The
sensor oligonucleotide spans the mutation site allowing the detec-
tion of a codon 12 or codon 13 mutation based on the distinct
melting temperatures (Tm) of wild-type KRAS and mutant KRAS.
DNA from a cell line carrying a mutation in KRAS codon 13 served
as a positive control.
EGFR mutation was detected by sequencing genomic DNA
puriﬁed as described for KRAS mutation detection. Exons 19
and 21 were ampliﬁed by PCR using the following exon ﬂanking
primer pairs: 19F, 59-CCTGAGGTTCAGAGCCATGGAC,
and 19R, 59-CAGCATGTGGCACCATCTCACAATTGC; and
21F, 59-CTTCCCATGATGATCTGTCCCTCACAGC, and 21R,
59-GGAGAGCATCCTCCCCTGCATGTGT. Amplicon sizes
were checked by agarose electrophoresis, which permitted
detection of large deletions. The amplicons were puriﬁed by
ethanol precipitation, sequenced using BigDye terminator
sequencing chemistry run on an ABI 3100 capillary analyser. The
resulting DNA sequences were analysed with Mutation
Surveyor V3.23 software.
Tissue microarray
The study group consisted of 51 wedge resections and lobecto-
mies performed at the University of Chicago Medical Center
from 1990 to 2008. These cases were divided into three groups:
(1) invasive adenocarcinoma with BAC pattern, (2) ‘pure BAC’
without invasive adenocarcinoma, and (3) adenocarcinoma
without BAC. Eleven of the pure BAC cases were non-mucinous
type (92%). There were lymph node metastases in three cases of
invasive adenocarcinoma. A morphologically representative area
of interest within each parafﬁn donor block was identiﬁed by
two pathologists (AHN and MT) under the microscope using an
H&E-stained section on a glass slide as a guide. From each case
a minimum of ﬁve tissue cylinders with a diameter of 1 mm
were arrayed into a recipient block using an automated tissue
microarrayer ATA-27 (Beecher Instruments, Sun Prairie,
Wisconsin, USA). In the case of adenocarcinoma with BAC
pattern, the cores were obtained as follows: two cores from
invasive tumour, two from BAC component, and one from
adjacent normal lung. In the case of pure BAC or invasive
adenocarcinoma without BAC, ﬁve tissue cylinders included
three cores from the tumour and two cores from adjacent
normal lung. A total of 270 tissue cores were arrayed on to the
two recipient TMA blocks, which were then cut into 4 mm thick
serial sections and subjected to IHC analysis.
Fluorescent in situ hybridisation and analysis
Two-colour FISH analysis was performed using the BAC probe
RP11-144B2, which localises to 12q24.23 and contains the full-
length paxillin gene, directly labelled with Spectrum Orange
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Ilinois, USA), together with CEP 12 directly labelled with
Spectrum Green (Abbott Molecular), which hybridises to the
alpha-12 centromeric region (12p11.1e12q11.1).
19 Slides were
pretreated using the Parafﬁn Pretreatment Kit (Abbott Molec-
ular). At least 18 interphase nuclei were analysed for each
patient. Only single, clearly deﬁned nuclei were scored; over-
lapping nuclei or clusters of nuclei were not analysed. Split
ﬂuorescence signals with similar intensity and diameter seen in
the same focal plane adjacent to each other were counted as one
(eg, see ﬁgure 3F). For most cases, small round diploid nuclei
likely to be inﬁltrating lymphocytes were used as an internal
control.
Paxillin and chromosome 12 gene copy number were deter-
mined by dividing the total number of ﬂuorescent signals corre-
sponding to paxillin (RP11e144B2) or alpha-12 (CEP 12),
respectively, by the total number of nuclei analysed for each
patient. Since paxillin gene copy number was heterogeneous
within individual tumour samples, equivocal cases of paxillin
gene copy number alteration were not included in our analysis if
wefailedtoobserveindividualnucleiwithmorethanﬁvecopiesof
paxillin or if nuclei with more than two copies of paxillin repre-
sent <30% of the total nuclei scored. FISH was validated by
scoring 437 and 417 normal nuclei for paxillin and alpha-12,
respectively. In this report, the averaged number of ﬂuorescent
signalsinnormalnucleiwas2.04forpaxillinand1.85foralpha-12,
and these averages were used for all subsequent analysis
of malignant nuclei. Unpaired Student t test was used to deter-
mine statistical signiﬁcance for each case: the copy number of
Table 1 Patient characteristics (n¼105)
Patient characteristic Distribution (n (%))
Gender
Male 73 (70)
Female 32 (30)
Age
#60 years 49 (47)
>60 years 56 (53)
Race
Black 3 (3)
Caucasian 102 (97)
Smoking history
Current smoker 36 (34)
Former smoker 66 (63)
Never smoked 3 (3)
Pack-years
#45 51 (49)
>45 50 (48)
Unknown 4 (4)
COPD
Yes 79 (75)
No 19 (18)
Unknown 8 (7)
Asbestos
Yes 50 (48)
No 37 (35)
Unknown 18 (17)
COPD, chronic obstructive pulmonary disease.
Figure 1 Paxillin is overexpressed in
premalignant epithelial lesions in high-risk
patients. Representative images of
transbronchial biopsy samples stained for
paxillin. Paxillin staining localises to the
cytoplasm and is enriched in the basal
layers of the respiratory mucosa
(arrows). The bottom row of pie graphs
describes quantitative paxillin staining
intensity in biopsy samples with
hyperplasia, squamous metaplasia or
goblet cell metaplasia morphology.
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individualcasewascomparedwiththeaveragecopynumberfrom
all normal nuclei (ie, 2.04 and 1.85 for paxillin and alpha-12,
respectively); this was done for every case analysed. When
possible, the average gene copy number of paxillin and alpha-12
from malignant nuclei measured from an individual case was
compared with the average copy number of paxillin and alpha-12
from normal nuclei measured from the same corresponding case.
In all instances, both methods were in complete statistical
agreement. For paxillin, unpaired Student t test between normal
and malignant nuclei with p<0.01 was interpreted as a gene copy
number alteration; for alpha-12, unpaired Student t test between
normal and malignant nuclei with p<0.01 was interpreted as
chromosome 12 polysomy. Paxillin ampliﬁcation was deﬁned as
apaxillingenecopynumberincreaseandchromosome12eusomy.
‘Polysomy’wasdeﬁnedasacopynumberincreaseinbothpaxillin
and chromosome 12. Loss of heterozygosity was deﬁned as a
decrease in paxillin gene copy number and chromosome 12
eusomy.
RESULTS
Histological changes and paxillin expression in patients at high
risk of developing lung cancer
From the initial cohort of 105 patients at high risk of developing
lung cancer (table 1), biopsy material from 92 patients was
suitable for histological and paxillin analysis. This resulted in
a total of 279 individual biopsy samples for analysis (table 2)
with between one and six (mean number of three) biopsy
specimens analysed for each patient. No histological abnormal-
ities were observed on any of the individual biopsy samples of
10 patients; the remaining patients had one or more biopsy
specimens containing a portion of histologically normal
appearing respiratory mucosa. Hence, most patients (89%) had
one or more foci of histologically abnormal mucosa.
A total of 173 histological normal biopsy specimens were
analysed for paxillin expression by IHC. In 74 of 92 patients
(80%), no paxillin expression was observed in histologically
normal surface epithelium (see ﬁgure 2A of Jagadeeswaran
et al
9), whereas weak, moderate and strong paxillin expression
was observed in 13 (14%), four (5%) and one (1%) patients,
respectively (data not shown). This showed that paxillin was
either not detectable or was weakly expressed in histologically
Table 2 Distribution of histological ﬁndings by patient
(n¼105) and biopsy (n¼279)
Histology Frequency (n) (%)
By patient
No sample/not analysed 13 12
Normal histology only 10 10
Hyperplasia only (H)y 16 15
Squamous metaplasia only (S)z 44
Goblet cell metaplasia only (G)x 55
H and S 12 11
H and Gx 24 23
S and G 2 2
H and S and Gx 19 18
Total 105 100
By biopsy*
Normal respiratory mucosa 173 62
Hyperplasia 168 60
Squamous metaplasia 69 25
Goblet cell metaplasia 99 35
Dysplasia 4 1.4
Carcinoma 3 1.0
*More than one histological feature is typically present on a single
biopsy specimen.
yIncludes one patient with dysplasia and two with carcinoma.
zIncludes one patient with carcinoma.
xIncludes one patient with dysplasia.
Figure 2 Preinvasive epithelial lesions
from high-risk patients overexpress
paxillin. Bronchoscopic biopsy samples
showing dysplasia (A,B) and carcinoma
(C,D). Note the large, irregular nuclei in
the upper portion of the respiratory
(white arrow) and mitotic ﬁgure
(arrowheads) mucosa in (A) and
(B). Paxillin staining is strongest
along the basal and parabasal layers
(arrows in D).
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patients, which is similar to our previous ﬁndings.
9
An increase in paxillin expression in biopsy samples
containing areas of abnormal histology was observed (ﬁgure 1).
Whereas 11% of all histologically normal appearing biopsy
samples showed moderate to strong concentrations of paxillin,
moderate to strong paxillin expression was observed in 78%,
81% and 93% of the hyperplastic, squamous metaplastic and
goblet cell metaplastic lesions, respectively. Paxillin expression
appeared strongest in the basal layer (arrows, ﬁgure 1). Four of
the 92 patients (4%) had areas of dysplasia (ﬁgure 2A,B) and
three (3%) had lung carcinoma (ﬁgure 2C,D). All of these patient
samples showed elevated levels of paxillin expression, and
expression appeared strongest along the basal layer at the
peripheral margins of the preinvasive lesions (black arrows,
ﬁgure 2D). Together, these ﬁndings indicate that, relative to
adjacent normal respiratory mucosa, paxillin expression was
upregulated in non-neoplastic precursor lesions before malignant
changes were microscopically evident and can remain elevated
during the formation of preinvasive epithelial lesions.
Dysplasia and carcinoma were associated with a long history
of smoking (table 3). On the other hand, hyperplasia, squamous
metaplasia and goblet cell metaplasia were associated with
a corresponding increase in mean smoking pack-year history,
indicating that hyperplastic changes occur earliest in smokers,
whereas goblet cell metaplasia occurs in the setting of a longer
smoking history. The highest levels of paxillin staining were
observed in patients with the longest smoking history. Stronger
paxillin staining was visible in 69% of biopsy samples from
current smokers (22/32) compared with 49% of biopsy samples
from former smokers (24/49) (p¼0.0395, c
2 test).
Gene copy number of paxillin correlates with histological
subtype and KRAS mutation
A pilot series of 11 human non-small cell lung cancer (NSCLC)
samples representing various histological subtypes were exam-
ined by FISH to determine if paxillin (12q24.23) gene copy
number alteration correlated with a speciﬁc histological subtype
of lung cancer (table 4). Paxillin gene copy number was increased
in two of four adenocarcinoma samples, whereas paxillin gene
copy number changes in other histological subtypes were not
observed. EGFR and KRAS mutation status were examined on
enriched tumour foci isolated using laser capture microscopy. A
KRAS mutation in codon 12/13 was detected in one of the two
adenocarcinomas cases with increased paxillin gene copy
number, indicating that KRAS muation
20 21 and altered paxillin
gene copy number are not mutually exclusive. No mutations in
exon 19 or exon 21 of EGFR in any samples were detected.
Paxillin locus is ampliﬁed in adenocarcinoma including pure BAC
subtype
On the basis of the relatively high frequency with which paxillin
gene copy number alterations were identiﬁed in lung adenocar-
cinoma in the initial small set of samples, together with our
Figure 3 Paxillin gene copy number is
increased in lung adenocarcinoma and
bronchioloalveolar carcinoma (BAC).
Representative DAPI (4’,6-diamidino-2-
phenylindole)-stained nuclei showing
FISH probes for paxillin (red) and alpha-
12 (green). Non-malignant nuclei exhibit
two ﬂuorescent signals for both paxillin
and alpha-12 (A). Primary lung
adenocarcinoma measuring <5 mm (B),
5e10 mm (C), >10 mm (D), pure BAC
(E) and metastatic adenocarcinoma (F).
Table 3 Pack-years of smoking by histology and paxillin
expression
Pack-year of smoking
Histology
Hyperplasia 14.7 (27.4)
Squamous metaplasia 41.0 (26.7)
Goblet cell metaplasia 56.9 (29.5)
Dysplasia/carcinoma 79.3 (56.0)
Values are mean (SD).
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cell lines,
9 FISH was used to examine paxillin copy number in 39
cases of adenocarcinoma comprising 27 cases of adenocarcinoma
with a BAC component and 12 cases of pure BAC (ﬁgure 3).
Compared with normal nuclei with two copies of paxillin
(ﬁgure 3A), 13/27 cases of adenocarcinoma (48%) (table 5) and
5/12 cases of pure BAC (42%) (table 6) showed altered paxillin
gene copy number. With the exception of two cases of pure BAC
(see below), all tumours showed increased paxillin gene copy
number. Three to six copies of paxillin were typically observed
(ﬁgure 3BeF); however, occasionally individual nuclei with up
to 16 ﬂuorescent signals corresponding to the paxillin locus were
observed. Two of three cases with lymph node metastases
showed increased paxillin gene copy number similar to the
corresponding primary tumour. Occasionally, individual tumour
specimens showed heterogeneous alterations in paxillin gene
copy number such that regions with increased paxillin copy
number were adjacent to regions with normal copy number.
As chromosomal instability is common in NSCLC,
22 23
chromosome 12 centromeric region was co-analysed to deter-
mine if increased paxillin gene copy number was a non-speciﬁc
consequence of chromosome 12 polysomy (see the Methods
section). For adenocarcinoma, 8/13 cases (62%) with increased
paxillin gene copy number showed chromosome 12 polysomy,
Table 4 Correlation of paxillin copy number (FISH) with EGFR (exon 19/21) and KRAS (codons12/13)
mutation
Tumour histology Paxillin FISH EGFR exon 19 EGFR exon 21 KRAS codons 12/13
Adenocarcinoma (1.5 cm), solid and
acinar types, with focal signet ring
features
Ampliﬁcation WT WT WT
Adenocarcinoma with BAC pattern* Ampliﬁcation WT WT Mutation
Adenocarcinoma (1.6 cm) Diploid WT WT WT
Adenocarcinoma (0.5 cm), acinar type Diploid WT WT WT
Large cell carcinoma (1.7 cm) Diploid WT WT WT
Squamous cell carcinoma (3.0 cm) Diploid WT WT NA
Focal squamous metaplasia with
dysplasia
Diploid WT WT WT
High-grade squamous cell carcinoma
(3.7 cm)
Diploid WT WT WT
Adenosquamous carcinoma (1.2 cm) Diploid WT WT WT
Adenocarinoma (3.5 cm) with
sarcomatoid changes
Diploid WT WT NA
Adenosquamous carcinoma (1.2 cm) Diploid WT WT WT
*Paxillin overexpression conﬁrmed with immunohistochemistry.
BAC, bronchioloalveolar carcinoma; FISH, ﬂuorescence in situ hybridisation; NA, KRAS PCR ampliﬁcation failed; WT, wild-type.
Table 5 Correlation of increased paxillin gene copy number with chromosome 12 and paxillin
expression in lung adenocarcinoma with BAC component
Case Histological component Paxillin p Value a-12 p Value Paxillin expression*
Reference Normal 2.04 1.85
1 BAC 2.50 <0.0001 2.03 0.035
INV 2.64 <0.0001 1.85 1 Weak
2 BAC 2.70 <0.0001 2.07 0.014 Moderate
3 INV 3.87 <0.0001 3.37 <0.0001 None
4 BAC 2.97 <0.0001 2.48 <0.0001
INV 4.30 <0.0001 0.05 <0.0001 Weak
5 BAC 3.92 <0.0001 2.92 <0.0001
INV 3.64 <0.0001 2.67 <0.0001 Weak
6 BAC 2.96 <0.0001 2.00 0.025
INV 2.35 0.011 2.04 0.035 Moderate
7 INV 2.59 <0.0001 2.11 0.0037 NA
8 INV 2.40 <0.0001 1.95 0.16 High
9 BAC 2.63 <0.0001 1.79 0.51
INV 2.65 <0.0001 2.00 0.12 Moderate
10 INV 2.97 <0.0001 2.68 <0.0001
LN 4.33 <0.0001 3.17 <0.0001 Weak
11 BAC 4.58 <0.0001 2.67 <0.0001 High
12 BAC 4.24 <0.0001 3.81 <0.0001
INV 5.48 <0.0001 4.59 <0.0001 None
13 INV 3.21 <0.0001 2.95 <0.0001
LN 3.19 <0.0001 2.67 <0.0001 None
The average number of ﬂuorescent signals per nuclei are given for paxillin and chromosome 12 (a-12).
*See the Methods section for description of expression levels.
BAC, bronchioloalveolar carcinoma; INV, non-BAC component; NA, immunohistochemistry for case 7 was not interpreted because of
technical difﬁculties.
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(p¼0.217, c
2 test). Of the ﬁve cases of pure BAC with altered
paxillin gene copy number, three showed increased paxillin gene
copy number and two demonstrated loss of heterozygosity for
paxillin (table 6). Of the cases of adenocarcinoma with a BAC
component, none showed loss of heterozygosity for paxillin. We
did not observe any tumour specimen with multiple copies of
chromosome 12 centromeric regions and two or fewer copies of
paxillin.
Paxillin protein concentrations were determined by IHC on
36/39 tumour specimens that were analysed by FISH (ﬁgure 4).
Alterations in paxillin gene copy number were seen in 17/36
cases, and ﬁve of these cases also showed paxillin overexpression
(table 5). Further analysis showed that 4/5 cases with paxillin
ampliﬁcation (ie, chromosome 12 eusomy) showed paxillin
overexpression (ie, cases 2, 6, 8 and 9 in table 5), whereas 1/7
cases with chromosome 12 polysomy showed paxillin over-
expression (ie, case 11 in table 5) (p¼0.046, Fisher exact test).
This ﬁnding suggests that paxillin overexpression in lung
adenocarcinoma is more likely to occur with relatively small
alterations in chromosome 12 that include the paxillin locus,
compared with genomic rearrangements involving the entire
chromosome 12.
DISCUSSION
This is the ﬁrst analysis of paxillin expression during the earliest
stages of lung cancer development. By analysing paxillin
expression in 279 biopsy specimens from 92 patients at high risk
of developing lung cancer, we demonstrate that paxillin is
overexpressed in the majority of premalignant lesions such as
hyperplasia, squamous metaplasia and goblet cell metaplasia. We
also observed that paxillin is overexpressed in preinvasive
epithelial lesions. We found that paxillin gene copy number is
often increased in the bronchioloalveolar subtype of lung
adenocarcinoma and pure BAC. We further identiﬁed a subset of
human lung adenocarcinomadcharacterised by relatively small-
scale rearrangements of chromosome 12 affecting the paxillin
locusdwhere paxillin overexpression correlated with increased
paxillin gene copy number.
On the basis of our previous work,
9 we hypothesised that
paxillin becomes overexpressed in premalignant lesions when
histological evidence of neoplasia is ﬁrst evident. Current models
suggest that lung cancer develops through a progressive
continuum of histological changes in normal respiratory mucosa
towards advancing grades: hyperplasia, squamous and/or goblet
cell metaplasia, dysplasia and AAH/carcinoma in situ.
72 4These
changes are in turn driven by an underlying accumulation of
molecular alterations that ultimately lead to microinvasive
NSCLC. Although these lesions are associated with the devel-
opment of NSCLC in smokers and other high-risk individuals
and are often identiﬁed in lung resections, they do not invariably
progress, and instead often regress after smoking cessation.
25
This ﬁnding underscores the variability in biological behaviour
of these lesions and emphasises the need to identify biomarkers
with diagnostic, prognostic and therapeutic utility. We observe
that paxillin is widely overexpressed in most premalignant
lesions of varying histological morphology. Since most of these
lesions will not go on to develop into lung cancer, our ﬁndings
indicate that paxillin overexpression is not a speciﬁc biomarker
for identifying premalignant lesions in high-risk patients.
Instead paxillin overexpression probably reﬂects a role related
to proliferation and survival associated with altered or damaged
respiratory epithelium secondary to smoking-related injury. This
is supported by the relative increase in paxillin expression in the
basal and parabasal layers and along the leading edges of invasive
lesions. Reserve progenitor cells are believed to reside in the basal
layer, and smoking elicits changes in gene and protein expression
in the epithelium of smokers associated with injury response
and proliferation.
26 Protein concentrations of Ki-67, a prolifera-
tion marker expressed in dividing cells but not resting cells,
measured in bronchial biopsy samples of current and former
smokers showed a similar expression pattern to paxillin
27 with
enhanced expression along the basal and parabasal layers.
Interestingly, Ki-67 was more highly expressed in current
smokers than former smokers. We also measured lower paxillin
expression in former smokers compared with current smokers.
However, the signiﬁcance of this observation is uncertain, as we
were unable to compare paxillin expression in former smokers
with biopsy material obtained when they actively smoked.
Increased paxillin expression is also observed in glomerular
immune injury, suggesting upregulation of integrin signalling in
response to accumulation of extracellular matrix proteins and
scarring.
28 Together, these ﬁndings support a role for paxillin
during epithelial response to injury in patients with a history of
exposure to cigarette smoke.
Table 6 Correlation of paxillin copy number variation with
chromosome 12 and paxillin expression in pure bronchioloalveolar
carcinoma lung cancer
Cases
Two copies paxillin 7
More than two copies paxillin 3
Chromosome 12 polysomy 3
Low paxillin expression 1
High paxillin expression 2
Chromosome 12 eusomy 0
Loss of heterozygosity 2
Chromosome 12 polysomy 0
Chromosome 12 eusomy 2
Low paxillin expression 2
High paxillin expression 0
Figure 4 Paxillin is overexpressed in adenocarcinoma and bronchio-
loalveolar carcinoma (BAC). Representative H&E and paxillin-stained
tissue microarray tissue cores from cases of adenocarcinoma with BAC
component and pure BAC are shown along with the distribution of
paxillin staining intensity.
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motifs, four C-terminal LIM domains, and several SH3 domains
which allow paxillin to form a large number of proteineprotein
interactions. The LIM3 domain targets paxillin to focal adhesion
sites, thereby regulating its subcellular localisation. Consequently,
paxillin is able to integrate multiple signalling pathways
within the cell by providing docking sites for common
signalling molecules and positioning them adjacent to acti-
vated receptors such as integrin heterodimers and growth
factor receptors at the cell membrane.
11 It would therefore
appear beneﬁcial for a cell to express paxillin during wound
healing in response to injury
29 as well as during malignant
transformation.
30e32 For example, the terminal LD4 domain of
paxillin binds the BH4 domain of Bcl-2, and this interaction
promotes survival and morphogenesis during kidney develop-
ment.
13 14 We have previously shown that paxillin colocalises
with Bcl-2 in NSCLC.
9 This raises the intriguing hypothesis
that paxillin overexpression in premalignant lesions promotes
survival via Bcl-2-mediated signalling. This interaction in turn
can facilitate tissue repair, as well as tumour development.
Nakanishi et al
33 demonstrated increasing levels of Bcl-2
expression in low-grade to high-grade AAH lesions and non-
mucinous BAC. Although we did not directly examine paxillin
and Bcl-2 colocalisation in the biopsy specimens, it is tempting
to speculate that this interaction may be an early event in
lung cancer development, and future studies can test this
prediction.
Consistent with our previous work
9 and the analysis
presented here, little to no paxillin expression is observed in
histologically normal respiratory epithelium. This is in marked
contrast with liver, where paxillin expression shows no statis-
tically signiﬁcant difference in tumour and adjacent non-tumour
liver tissue,
31 indicating that baseline levels of paxillin expression
in normal cells are tissue dependent. We also observed a signiﬁ-
cant correlation between paxillin overexpression and increased
paxillin gene copy number in a subset of lung adenocarcinoma
with a diploid complement of chromosome 12. This ﬁnding
suggests alternative mechanisms for paxillin overexpression
depending on the tumour genotype. In cases of polysomy for
chromosome 12, the lack of correlation between paxillin gene
copy number and paxillin overexpression suggests that addi-
tional mutations in other key genes develop during tumorigen-
esis, at which point paxillin overexpression becomes dispensable.
KRAS is located on chromosome 12 and is a known driver
mutation in lung cancer, raising the possibility that paxillin
overexpression is no longer necessary when tumours become
polysomic for chromosome 12. Interestingly, we only observed
paxillin loss of heterozygosity in pure BAC tumours, which also
failed to overexpress paxillin. In summary, this is the ﬁrst
description of paxillin overexpression in the earliest morpho-
logical changes leading up to the development of lung cancer. We
also identify a subset of lung adenocarcinoma in which changes
in paxillin gene copy number correlate with paxillin over-
expression, and future studies will address the clinical signiﬁ-
cance of this observation.
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